PharmaMar
a marine natural-products drug developer advancing clinical candidates including PM534 and PM742, which announced an AI collaboration with Globant in March 2026 aimed at accelerating oncology research with claimed 15x-faster insight generation and over 90% accuracy in its agentic research workflow.
- Country
- Spain
Commercial
Marine natural-product oncology pipeline (PM534, PM742); AI collaboration with Globant, Mar 2026
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| marine-biotech | ✓ | ✓ | ✓ |
Regulatorsun-doalosepa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Marine genomic prospecting & the BBNJ treaty | marine-biotech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.